Help us: Donate
Follow us on:
×

Tag: resTORbio

January 24, 2020
The Longevity Therapeutics conference enters its second year, opening its doors on January 28th for a three-day event focused on aging research. If you are interested in the actual science happening in the field with no snake oil in sight, then this is the West Coast conference to attend. With over 80 speakers, including researchers,...
November 18, 2019
ResTORbio announced on Friday 15th that its current phase 3 drug trial for respiratory tract infections did not achieve its primary goal. The drug showed promise in earlier phases of testing, but sadly failed to reduce the incidence of respiratory tract infections in patients aged 65 and above. A setback for RTB101 This news has...
April 16, 2019
Rapamycin is a promising anti-aging therapeutic derived from a bacterium that was first found on Easter Island (it's named for Rapa Nui, the official name of Easter Island). It inhibits mTOR (mechanistic target of rapamycin), thus inhibiting the immune system response that would, in some cases, lead to organ rejection. This is the on-label, FDA-approved...
March 19, 2019
Last year, resTORbio announced the positive results of its phase 2b human trial, which targeted the aging immune system with an immune system-boosting drug. Now, the company has announced the news that its therapy is moving to a phase 3 study later this year after successful negotiation with the FDA. Targeting the mTOR pathway of...
July 25, 2018
Today, we are pleased to announce that the results are in from a human trial that targets the aging immune system and that an immune system-boosting drug appears to be effective. Targeting TORC1 to boost the immune system As we age, the immune system becomes increasingly poor and unable to detect and fight infections. This...
April 10, 2017
The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis. PureTech have recently announced a joint venture with Novartis called resTORbio and are...